Mail

ARRY - Array BioPharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

47.85

0.00 (0.00%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	47.85
Open	47.96
Bid	0.00 x 21500
Ask	0.00 x 1400
Day's Range	47.85 - 47.97
52 Week Range	12.56 - 47.98
Volume	20,604,596
Avg. Volume	7,360,322

Market Cap	10.675B
Beta (3Y Monthly)	1.65
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Trade prices are not sourced from all markets

All

News

Press Releases

ACCESSWIRE
Rigrodsky & Long, P.A. Files Class Action Suit Against Array BioPharma Inc.
WILMINGTON, DE / ACCESSWIRE / July 10, 2019 / Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders ...
GlobeNewswire
Legal Investigation Alert: Halper Sadeh LLP Continues Investigating Whether the Sale of Array BioPharma Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARRY
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Array BioPharma Inc. (“Array” or the “Company”) (ARRY) to Pfizer Inc. (“Pfizer”) is fair to Array shareholders. On behalf of Array shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an Array shareholder and would like to discuss your legal rights and options, please visit Array Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
PR Newswire
Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
- As previously announced, BRAFTOVI combinations showed statistically significant improvement in OS and ORR versus control - - Data supports potential to be the first chemotherapy-free, targeted regimen ...
PR Newswire
Lifshitz & Miller LLP Announces Investigation of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., and Raytheon Company, Shutterfly, Inc., Sotheby's and Stewardship Financial Corporation, and Zimmer Biomet Holdings, Inc.
NEW YORK , June 27, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of ARRY to ...
GlobeNewswire
ARRY, RTN, DATA and MDSO SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
WILMINGTON, Del., June 27, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Array BioPharma Inc. (NASDAQ GM: ARRY) regarding possible breaches of.
PR Newswire
Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
BOULDER, Colo. , June 25, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated data from the combination of BRAFTOVI ® (encorafenib), a BRAF inhibitor, MEKTOVI ...
ACCESSWIRE
CJ, ARRY, BID INVESTOR ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - CJ, ARRY, BID
NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating C&J Energy Services, Inc. (NYSE: CJ), Array BioPharma Inc. (NASDAQ: ARRY), ...
PR Newswire
URGENT ALERT: Monteverde & Associates PC Launches an Investigation Regarding the Following Merger
NEW YORK , June 21, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition
NEW YORK, June 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (ARRY) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (PFE).
GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Array BioPharma Inc. (NASDAQ: ARRY) on Behalf of Array Shareholders and Encourages Array Investors to Contact the Firm
NEW YORK, June 17, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Array BioPharma, Inc. (NASDAQ: ARRY) on behalf of.
GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Array BioPharma Inc. to Pfizer Inc. is Fair to Shareholders
NEW YORK, June 17, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Array BioPharma Inc. (“Array.
GlobeNewswire
ARRAY BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
WILMINGTON, Del., June 17, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Array BioPharma Inc. (NASDAQ GM: ARRY)? Did you purchase any of your shares prior to June.
GlobeNewswire
Array Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Array BioPharma Inc. is Fair to Shareholders – ARRY
NEW YORK, June 17, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Array BioPharma Inc. (“Array” or the “Company”) (NASDAQ:.
PR Newswire
Pfizer to Acquire Array BioPharma
NEW YORK, and BOULDER, Colo., June 17, 2019 /PRNewswire/ -- Pfizer Inc (PFE) and Array BioPharma Inc. (ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion.
PR Newswire
Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference
BOULDER, Colo. , June 4, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Operating Officer, Andrew Robbins , will speak at the Goldman Sachs 40th Annual Global Healthcare ...
PR Newswire
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
BOULDER, Colo. , May 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Jefferies 2019 Global Healthcare Conference ...
PR Newswire
Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months - - Landmark analysis estimates 47% and 39% of patients ...
PR Newswire
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be ...
PR Newswire
Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
BOULDER, Colo. , May 9, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Bank of America Merrill Lynch 2019 Health ...
PR Newswire
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter - - BEACON CRC Phase 3 trial interim analysis remains on track to report out this ...
PR Newswire
Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019
BOULDER, Colo. , April 30, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results ...
PR Newswire
BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer
BOULDER, Colo. , March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network ® (NCCN ® ) has updated their Clinical Practice Guidelines ...
PR Newswire
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
BOULDER, Colo. , March 5, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference ...
GlobeNewswire
Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.